绥美凯治什么？

It has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. Wim, head of medical affairs and vice president of GSK China/Hong Kong Dr. Swyzen, MD, said, "Through effective HIV drug treatment, the lifespans of AIDS patients and healthy people are getting closer and closer. Drug compliance and convenience of medication are playing an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day or one tablet at a time on the Chinese market. The approval of Suimeikan fills this gap and meets the urgent need for convenient medication use by doctors and patients." Today we will learn about what Suimeikan treats?

Suimeikai is indicated for the treatment of adults and adolescents over 12 years old (with a body weight of at least 40 kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir.

Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.

HIV is a virus that attacks the body's immune system. It takes the most important CD4 T lymphocytes in the human immune system as its main attack target, destroys these cells in large quantities, and causes the human body to lose its immune function. Therefore, the human body is susceptible to various diseases, and malignant tumors can occur, with a high mortality rate. The average incubation period of HIV in the human body is 8 to 9 years. In 2018, GSK announced the launch of integrase DTG (Trivac) in China. This treatment has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. Trimic uses DTG, an integrase inhibitor, as the core drug, and a treatment plan with two backbone drugs, abacavir and lamivudine, and is made into a single-tablet treatment for promotion, making the core drug a great progress in HAART treatment. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.

The above is the content of the indications, I hope it can help you!